Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq:
ALKS) today announced results from the long-term extension of the
DURATION-1 study, which showed that BYDUREON™ (exenatide
extended-release for injectable suspension), the first and only
once-weekly treatment for type 2 diabetes, was associated with
clinically significant and sustained improvements in glycemic control
during four years of treatment in adults with type 2 diabetes.
In the study, being presented at the 72nd Scientific Sessions of the
American Diabetes Association in Philadelphia, patients completing four
years of BYDUREON treatment experienced clinically significant
improvements in A1C (1.7 percentage points) and fasting plasma glucose
(-37 mg/dL) from baseline. A1C is a measure of average blood sugar over
three months. Although BYDUREON is not indicated for weight loss,
patients treated with BYDUREON also lost an average of 5.5 pounds from
baseline.